title: Safety of a peanut oral immunotherapy protocol in children with peanut allergy.
abstract: BACKGROUND
  Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen that could potentially cause a serious reaction, the safety of OIT is of particular concern.
  
  
  OBJECTIVE
  The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study.
  
  
  METHODS
  Skin, upper respiratory tract, chest, and abdominal symptoms were recorded with initial escalation day and buildup phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of these data was performed.
  
  
  RESULTS
  Twenty of 28 patients completed all phases of the study. During the initial escalation day, upper respiratory tract (79%) and abdominal (68%) symptoms were the most likely symptoms experienced. The risk of mild wheezing during the initial escalation day was 18%. The probability of having any symptoms after a buildup phase dose was 46%, with a risk of 29% for upper respiratory tract symptoms and 24% for skin symptoms. The risk of reaction with any home dose was 3.5%. Upper respiratory tract (1.2%) and skin (1.1%) symptoms were the most likely after home doses. Treatment was given with 0.7% of home doses. Two subjects received epinephrine after 1 home dose each.
  
  
  CONCLUSIONS
  Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare.
authors.affiliation: Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Alison M
authors.initials: AM
authors.lastname: Hofmann
authors.forename: Amy M
authors.initials: AM
authors.lastname: Scurlock
authors.forename: Stacie M
authors.initials: SM
authors.lastname: Jones
authors.forename: Kricia P
authors.initials: KP
authors.lastname: Palmer
authors.forename: Yuliya
authors.initials: Y
authors.lastname: Lokhnygina
authors.forename: Pamela H
authors.initials: PH
authors.lastname: Steele
authors.forename: Janet
authors.initials: J
authors.lastname: Kamilaris
authors.forename: A Wesley
authors.initials: AW
authors.lastname: Burks
mesh_terms: D000284:Administration, Oral; D000420:Albuterol / Q000008:administration & dosage; D000485:Allergens / Q000008:administration & dosage*; D018926:Anti-Allergic Agents / Q000008:administration & dosage; D010367:Arachis / Q000276:immunology*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic / Q000379:methods*; D004155:Diphenhydramine; D004837:Epinephrine / Q000008:administration & dosage; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D021183:Peanut Hypersensitivity / Q000628:therapy*
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents; D001993:Bronchodilator Agents; D007073:Immunoglobulin E; D004155:Diphenhydramine; D000420:Albuterol; D004837:Epinephrine